Back to News
Market Impact: 0.1
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
Source: GlobeNewswire
Healthcare & Biotech
The Phase 1/2 ABILITY-1 clinical trial is evaluating MDNA11 in expansion cohorts of patients with advanced or metastatic gastrointestinal, endometrial, and melanoma cancers. The article provides no trial results or other outcome data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Vaxcyte shares surge on late-stage vaccine trial success
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Vendor Landscape for Institutional Investment Teams
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk